![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Roche, Upsher-Smith Subsidiary Partner to Develop VAP-1 Inhibitor
Roche, Upsher-Smith Subsidiary Partner to Develop VAP-1 Inhibitor
![roche.gif](https://www.fdanews.com/ext/resources/test/Device_Images/roche.gif?t=1600727553&width=430)
Swiss drug giant Roche has partnered with Upsher-Smith Laboratories’ UK subsidiary Proximagen to develop a novel, oral small molecule inhibitor of vascular adhesion protein 1.
As part of the agreement, Roche obtains a worldwide exclusive license to develop and commercialize the compound — a cell-adhesion molecule that may be effective in the treatment of inflammatory disease — currently in Phase 2 trials.
Roche will be responsible for late-stage development of the therapy and will pay undisclosed upfront and milestone payments to Proximagen.
Upcoming Events
-
21Oct